Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CLX-0901 (Calyx Therapeutics).

D Barlocco1

  • 11st Chim Farmaceutico/Tossicologico, University of Milan, Italy. daniela.barlocco@unimi.it

Current Opinion in Investigational Drugs (London, England : 2000)
|September 25, 2001
PubMed
Summary

Calyx Therapeutics is developing CLX-0901, a synthetic insulin sensitizer, for diabetes treatment. Early studies show it is safe and well-tolerated, with Phase II trials now underway.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Designed multiple ligands: basic research vs clinical outcomes.

Current medicinal chemistry·2012
Same author

Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target.

Current medicinal chemistry·2008
Same author

Thymidylate synthase structure, function and implication in drug discovery.

Current medicinal chemistry·2005
Same author

Semicarbazide-sensitive amine oxidase: current status and perspectives.

Current medicinal chemistry·2004
Same author

Selective ACAT inhibitors as promising antihyperlipidemic, antiathero-sclerotic and anti-Alzheimer drugs.

Mini reviews in medicinal chemistry·2003
Same author

Characterization and pharmacological actions of tecostanine, an alkaloid of Tecoma stans.

Die Pharmazie·2003

Area of Science:

  • Pharmacology
  • Drug Development
  • Metabolic Diseases

Background:

  • Calyx Therapeutics is investigating novel antidiabetic agents.
  • CLX-0901 is a synthetic analog of CLX-0900, a compound originally derived from a plant source.
  • The development focuses on insulin sensitizers to manage diabetes.

Purpose of the Study:

  • To evaluate the safety and tolerability of CLX-0901 as an antidiabetic agent.
  • To advance CLX-0901 through clinical trials for potential diabetes treatment.
  • To explore a pipeline of other antidiabetic compounds.

Main Methods:

  • Phase I and toxicological studies were conducted.
  • Clinical Phase II studies have commenced.
  • Chemical synthesis of analogs from natural product leads.

Main Results:

  • Phase I and toxicological assessments demonstrated that CLX-0901 is safe and well-tolerated.
  • Successful initiation of Phase II clinical trials as of March 2001.
  • Identification of a synthetic analog with potential therapeutic benefits.

Conclusions:

  • CLX-0901 shows promise as a safe and effective antidiabetic agent.
  • The progression to Phase II studies supports its potential for treating diabetes.
  • Calyx Therapeutics maintains a broad research program in antidiabetic drug discovery.

Related Experiment Videos